MARKET

ADMA

ADMA

ADMA Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.760
-0.110
-5.88%
After Hours: 1.780 +0.02 +1.14% 19:50 04/09 EDT
OPEN
1.850
PREV CLOSE
1.870
HIGH
1.850
LOW
1.750
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
1.570
MARKET CAP
213.44M
P/E (TTM)
-1.9818
1D
5D
1M
3M
1Y
5Y
Hyperimmune Globulins Market Size is Determined to cross a value of 2002.1 Million USD by 2025
Apr 09, 2021 (Market Insight Reports) -- Selbyville, Delaware. The Hyperimmune Globulins market research report delivers a thorough analysis of this business...
Market Insight Reports · 2d ago
Hyperimmune Serum Market to Witness Huge Growth by 2026 | Grifols, Biotest, Kamada, ADMA Biologics
Apr 08, 2021 (Market Insight Reports) -- Hyperimmune Serum Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition...
Market Insight Reports · 3d ago
Primary Immunodeficiency Diseases Treatment Market Size 2021: Market Share, Top Companies report covers are CSL Behring,Grifols,Pfizer,Shire,Abbott,ADMA Biolo
Apr 08, 2021 (The Expresswire) -- “ Primary Immunodeficiency Diseases Treatment Market “ Size, Status and Market Insights 2021, ,Primary Immunodeficiency...
The Express Wire · 3d ago
Global Intravenous Immunoglobulins Market Size, Share, Value, and Competitive Landscape 2020
Apr 05, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 6d ago
Jefferies Thinks ADMA Biologics’ Stock is Going to Recover
Jefferies analyst Anthony Petrone maintained a Buy rating on ADMA Biologics (ADMA) on March 22 and set a price target of $10.00. The company's shares
SmarterAnalyst · 6d ago
The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 30)
Benzinga · 03/31 11:41
Global Hyperimmune Serum Market 2020 Industry Outlook, Key Players, Segmentation Analysis, Business Growth and Forecast to 2025
Mar 29, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has added a new key research report entitled Global Hyperimmune Serum Market Growth...
CDN Newswire · 03/29 17:03
DJ ADMA Biologics Is Maintained at Outperform by Raymond James
Dow Jones · 03/26 11:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMA. Analyze the recent business situations of ADMA Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMA stock price target is 8.67 with a high estimate of 11.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 144
Institutional Holdings: 53.03M
% Owned: 43.73%
Shares Outstanding: 121.28M
TypeInstitutionsShares
Increased
36
2.11M
New
18
953.12K
Decreased
23
1.65M
Sold Out
18
2.52M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.53%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Chairman/Independent Director
Steven Elms
President/Chief Executive Officer/Co-Founder/Director
Adam Grossman
Vice Chairman/Co-Founder/Director
Jerrold Grossman
Chief Financial Officer/Executive Vice President
Brian Lenz
Executive Vice President/Chief Scientific Officer
James Mond
Independent Director
Martha Demski
Independent Director
Bryant Fong
Independent Director
Lawrence Guiheen
No Data
  • All
  • Financials
  • Insiders
More
About ADMA
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMA stock methods without spending real money on the virtual paper trading platform.